Answer
Caplacizumab’s half-life depends on its concentration and the level of its target, von Willebrand factor, with higher von Willebrand factor antigen levels increasing the fraction of drug–target complex retained in circulation.
Sources for this answer
- Cablivi 10 mg powder and solvent for solution for injectionSANOFI · emc · SmPC §5.2 Pharmacokinetic properties · Version 10Document updated
Sources checked